Home Biosimilar Antibodies Neuronal Signaling Beta Amyloid Lecanemab (Anti-Amyloid Beta)
For research use only. Not for use in humans.

Lecanemab (Anti-Amyloid Beta)

Synonyms: BAN-2401

Lecanemab (Anti-Amyloid Beta) is a humanized IgG1 monoclonal antibody targeting soluble aggregated amyloid beta (Aβ). It can be used for the research of Alzheimer's Disease. MW :147.06 KD.

Lecanemab (Anti-Amyloid Beta)

4 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 5.451mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation Beta Amyloid Others
DAPT 404 Notch
RO4929097 (RG-4733) 126 γ secretase,Notch
Semagacestat (LY450139) 22 Notch
MK-0752 23
Avagacestat (BMS-708163) 22
LY2811376 19 BACE1
CRANAD-2 0
Hoechst 34580 2
Frentizole 0
Simufilam 1
Ginsenoside Rg1 7 NF-κB
Ginsenoside Re 2 NF-κB,JNK
Tabersonine hydrochloride 2
EUK 134 8
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Lecanemab (Anti-Amyloid Beta) is a humanized IgG1 monoclonal antibody targeting soluble aggregated amyloid beta (Aβ). It can be used for the research of Alzheimer's Disease. MW :147.06 KD.
References

Product Details

CAS No. 1260393-98-3
Isotype Human IgG1
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07544953 NOT_YET_RECRUITING Drug: Lecanemab Parkinson Disease Yonsei University 2026-05
NCT06384573 ACTIVE_NOT_RECRUITING Drug: lecanemab Alzheimer's Disease; Dementia; Alzheimer's Disease, Familial Washington University School of Medicine 2024-06-10 PHASE3
NCT05469009 ACTIVE_NOT_RECRUITING Drug: Aducanumab|Drug: Lecanemab Mild Cognitive Impairment; Alzheimer Disease 1 Ali Rezai 2022-07-14 EARLY_PHASE1
NCT03887455 ACTIVE_NOT_RECRUITING Drug: Lecanemab IV|Drug: Placebo|Drug: Lecanemab SC Early Alzheimer's Disease Eisai Inc. 2019-03-27 PHASE3
NCT07688460 RECRUITING Drug: Lecanemab Alzheimer Disease The Fourth Affiliated Hospital of Zhejiang University School of Medicine 2026-07-10 PHASE4
NCT04468659 ACTIVE_NOT_RECRUITING Drug: Lecanemab|Drug: Placebo Preclinical Alzheimer's Disease; Early Preclinical Alzheimer's Disease Eisai Inc. 2020-07-14 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-04-22)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.